Invesco Ltd. Nektar Therapeutics Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Nektar Therapeutics stock. As of the latest transaction made, Invesco Ltd. holds 646,808 shares of NKTR stock, worth $601,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares

646,808

Previous 644,226 0.4%

Holding current value

$601,531

Previous $798,000 5.26%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.11 - $1.48 $2,866 - $3,821	2,582 Added 0.4%	646,808 $840,000
Q2 2024 Aug 13, 2024	BUY	$0.9 - $1.83 $106,094 - $215,725	117,883 Added 22.4%	644,226 $798,000
Q1 2024 May 14, 2024	BUY	$0.49 - $0.96 $108,996 - $213,544	222,442 Added 73.2%	526,343 $489,000
Q4 2023 Feb 12, 2024	SELL	$0.42 - $0.57 $23,287 - $31,604	-55,446 Reduced 15.43%	303,901 $170,000
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $2.64 Million - $5.43 Million	-5,176,083 Reduced 93.51%	359,347 $215,000
Q2 2023 Aug 11, 2023	SELL	$0.53 - $1.03 $16.9 Million - $32.9 Million	-31,947,156 Reduced 85.23%	5,535,430 $3.21 Million
Q1 2023 May 12, 2023	BUY	$0.64 - $3.15 $99,272 - $488,605	155,113 Added 0.42%	37,482,586 $26.2 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $129,570 - $273,183	63,828 Added 0.17%	37,327,473 $84.4 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $101,165 - $171,048	33,278 Added 0.09%	37,263,645 $119 Million
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $529 - $1,030	-167 Reduced -0.0%	37,230,367 $141 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $1.41 Million - $4.65 Million	339,040 Added 0.92%	37,230,534 $201 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $13.2 Million - $22.5 Million	1,220,307 Added 3.42%	36,891,494 $498 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $167,400 - $241,302	12,808 Added 0.04%	35,671,187 $641 Million
Q2 2021 Aug 17, 2021	BUY	$16.52 - $20.4 $3.45 Million - $4.26 Million	208,985 Added 0.59%	35,658,379 $612 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $125,110 - $192,350	-7,555 Reduced 0.02%	35,449,394 $709 Million
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $3.7 Million - $4.46 Million	-234,309 Reduced 0.66%	35,456,949 $603 Million
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $41.7 Million - $62.2 Million	2,510,614 Added 7.57%	35,691,258 $592 Million
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $12.5 Million - $17.4 Million	-740,754 Reduced 2.18%	33,180,644 $768 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $33.2 Million - $64.1 Million	2,292,264 Added 7.25%	33,921,398 $605 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $47.8 Million - $69.7 Million	-3,014,252 Reduced 8.7%	31,629,134 $683 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $191 Million - $410 Million	11,300,367 Added 48.41%	34,643,386 $631 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $661 Million - $774 Million	21,326,731 Added 1057.72%	23,343,019 $831 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $6.6 Million - $9.68 Million	208,932 Added 11.56%	2,016,288 $67.7 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $55 Million - $102 Million	1,807,356 New	1,807,356 $59.4 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account